These findings could suggest that GLP-1 analogues, such as liraglutide and exendin-4, may be especially successful weight loss therapies in individuals more likely to exhibit decreases in GLP-1 secretion (e.g., people with obesity and those who habitually consume high levels of dietary added sugar), but this prediction requires further investigation with randomized controlled studies. The gene discussed is GLP1R; the disease is obesity disorder.